What is Cellectar Biosciences INC NEW's earnings per share (EPS)?

Cellectar Biosciences INC NEW (CLRB) reported diluted earnings per share of -$8.35 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cellectar Biosciences INC NEW (CLRB) Financials

CLRB

FY2025 annual

Net Income -$21.8M +51.1% YoY

EPS (Diluted) -$8.35 YoY not available

Free Cash Flow -$23.1M +51.5% YoY

Operating Cash Flow -$23.1M +51.4% YoY

Market Cap $13.5M as of Oct 13, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.5x on $29.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLRB SEC filings page.

This page shows Cellectar Biosciences INC NEW (CLRB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLRB FY2025 2026-10-03

Cellectar remains a development-stage company: 2025 losses narrowed mainly because spending fell, while financing still supplied cash.

Cash conversion closely follows reported losses: the 2025 net loss was $21.8M against operating cash outflow of $23.1M, and the 2024 figures were similarly close. With capital spending only $6K in 2025, cash use appears driven mainly by ongoing operations rather than a heavy investment program.

The reduction in 2025 losses reflects a smaller operating cost base: R&D fell to $11.5M from $26.1M, while SG&A fell to $11.5M from $25.6M. Because reported revenue is absent, this is evidence of spending restraint, not demonstrated commercial growth.

The balance sheet recovered from its 2023 strain: 2025 current assets of $14.0M exceeded current liabilities of $4.7M, versus a 0.4x current ratio in 2023. That improvement coincided with $13.0M of financing inflows, and the reported liquidity comparison equals 6.8 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

Cellectar Biosciences INC NEW does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Cellectar Biosciences INC NEW passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Cellectar Biosciences INC NEW reported a net loss of $21.8M while operations used $23.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$6.9M

YoY-27.2%

QoQ-22.6%

Cellectar Biosciences INC NEW reported -$6.9M in net income in Q2 2026. This represents a decrease of 27.2% from the same quarter a year earlier. Against the prior quarter it is down 22.6%.

EPS (Diluted)

-$0.57

Cellectar Biosciences INC NEW earned -$0.57 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$6.0M

QoQ-23.9%

Cellectar Biosciences INC NEW recorded an outflow of $6.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is down 23.9%.

Cash & Debt

$34.0M

YoY+207.9%

QoQ+307.3%

5Y CAGR-6.2%

10Y CAGR+15.7%

Cellectar Biosciences INC NEW held $34.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

5Y CAGR-31.2%

10Y CAGR+5.8%

Cellectar Biosciences INC NEW had 9M shares outstanding in Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-23.2%

YoY+66.3pp

QoQ+146.3pp

Cellectar Biosciences INC NEW's ROE was -23.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 66.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 146.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$4.6M

YoY+90.7%

QoQ+51.5%

Cellectar Biosciences INC NEW invested $4.6M in research and development in Q2 2026. This represents an increase of 90.7% from the same quarter a year earlier. Against the prior quarter it is up 51.5%.

Capital Expenditures

QoQ-100.0%

Cellectar Biosciences INC NEW reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q2 2026.

CLRB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLRB quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
R&D Expenses	N/A	$11.5M-56.0%	$26.1M-4.1%	$27.3M+49.3%	$18.3M+3.9%	$17.6M+73.4%	$10.1M+12.7%	$9.0M+31.6%	$6.8M-27.8%	$9.5M+99.3%	$4.8M-7.9%	$5.2M-13.5%	$6.0M-13.1%	$6.9M+33.9%	$5.1M+42.3%	$3.6M
SG&A Expenses	N/A	$11.5M-55.2%	$25.6M+119.3%	$11.7M+10.9%	$10.5M+61.2%	$6.5M+27.1%	$5.1M-0.6%	$5.2M+7.5%	$4.8M+16.6%	$4.1M-12.0%	$4.7M+38.4%	$3.4M-8.3%	$3.7M-16.7%	$4.4M+22.4%	$3.6M+34.9%	$2.7M
Operating Income	N/A	-$23.0M+55.6%	-$51.8M-32.9%	-$39.0M-35.2%	-$28.8M-19.4%	-$24.1M-57.8%	-$15.3M-7.8%	-$14.2M-6.4%	-$13.3M+2.0%	-$13.6M-43.9%	-$9.4M-7.9%	-$8.8M+11.5%	-$9.9M+20.2%	-$12.4M-41.7%	-$8.8M-24.4%	-$7.0M
EBITDA	N/A	-$22.8M+55.8%	-$51.5M-32.8%	-$38.8M-35.2%	-$28.7M-19.5%	-$24.0M-58.3%	-$15.1M-7.9%	-$14.0M-6.0%	-$13.2M-9.9%	-$12.1M-32.6%	-$9.1M-8.3%	-$8.4M+11.8%	-$9.5M+20.5%	-$12.0M-45.0%	-$8.3M-28.0%	-$6.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K-62.5%	$4K-76.5%	$17K+88.9%	$9K0.0%	$9K-48.6%	$18K
Income Tax	N/A	N/A	$66K+210.0%	-$60K0.0%	-$60K	N/A	N/A	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$1.1M
Net Income	N/A	-$21.8M+51.1%	-$44.6M-17.4%	-$38.0M-19.5%	-$31.8M-31.8%	-$24.1M-59.8%	-$15.1M-7.1%	-$14.1M-6.4%	-$13.2M+2.4%	-$13.6M-119.4%	-$6.2M-12.5%	-$5.5M+31.8%	-$8.1M+25.3%	-$10.8M-22.6%	-$8.8M-18.3%	-$7.4M
EPS (Basic)	N/A	-$8.35+77.1%	-$36.52-943.4%	-$3.50+22.4%	-$4.51-3.7%	-$4.35-472.4%	-$0.76	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$8.35	-$41.89	-$3.50	-$4.51	-$4.35-136.4%	-$1.84	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	3M	1M	12M	7M	6M-72.0%	20M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$4.6M+90.7%	$3.0M-12.3%	N/A	$2.5M-54.1%	$2.4M-67.5%	$3.4M-51.6%	N/A	$5.5M-21.9%
SG&A Expenses	$2.6M-27.7%	$2.8M-6.3%	N/A	$2.3M-70.3%	$3.6M-42.6%	$3.0M-39.5%	N/A	$7.8M+229.3%
Operating Income	-$7.2M-19.2%	-$5.8M+9.5%	N/A	-$4.9M+63.6%	-$6.0M+55.9%	-$6.4M+46.7%	N/A	-$13.3M-41.6%
EBITDA	N/A	N/A	N/A	-$4.8M+63.8%	-$6.0M+56.1%	-$6.3M+46.7%	N/A	-$13.3M-41.5%
Net Income	-$6.9M-27.2%	-$5.7M+14.4%	N/A	-$4.4M+69.7%	-$5.4M-492.6%	-$6.6M+75.2%	N/A	-$14.7M+16.3%
EPS (Basic)	-$0.57+83.2%	-$1.33+69.1%	-$0.53-211.8%	-$1.41+87.4%	-$3.39-340.3%	-$4.30-372.5%	-$0.17+58.5%	-$11.18-621.3%
EPS (Diluted)	-$0.57	-$1.33	-$0.53	-$1.41	-$3.39	-$4.30	-$0.10+75.6%	-$12.13
Diluted Shares (Avg)	12M	4M	N/A	3M	2M	2M	N/A	1M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

CLRB Balance Sheet

CLRB quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$15.0M-41.2%	$25.5M+111.0%	$12.1M-44.1%	$21.6M-42.0%	$37.2M-36.6%	$58.7M+378.8%	$12.3M-18.6%	$15.1M+17.0%	$12.9M-16.0%	$15.3M+101.7%	$7.6M-43.4%	$13.4M+96.9%	$6.8M-40.6%	$11.5M+8.7%	$10.6M
Current Assets	$14.0M-42.1%	$24.3M+132.0%	$10.5M-49.1%	$20.5M-43.9%	$36.6M-36.9%	$57.9M+408.9%	$11.4M-18.4%	$14.0M+33.2%	$10.5M-14.1%	$12.2M+191.7%	$4.2M-56.9%	$9.7M+250.4%	$2.8M-46.0%	$5.1M-11.8%	$5.8M
Cash & Equivalents	$13.2M-43.3%	$23.3M+143.5%	$9.6M-51.9%	$19.9M-44.4%	$35.7M-37.5%	$57.2M+438.5%	$10.6M-19.9%	$13.3M+32.5%	$10.0M-12.6%	$11.4M+192.5%	$3.9M-58.5%	$9.4M+289.6%	$2.4M-48.3%	$4.7M-15.0%	$5.5M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0-100.0%	$24K-68.6%	$75K0.0%	$75K0.0%	$75K0.0%	$75K-86.1%	$541K+16.1%	$466K	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M
Total Liabilities	$5.1M-48.4%	$9.8M-62.1%	$25.9M+114.5%	$12.1M+190.0%	$4.2M+7.6%	$3.9M+21.1%	$3.2M+78.0%	$1.8M-15.3%	$2.1M+18.6%	$1.8M-70.0%	$5.9M-11.5%	$6.7M+31.4%	$5.1M+287.7%	$1.3M+22.0%	$1.1M
Current Liabilities	$4.7M-49.4%	$9.4M-63.0%	$25.4M+120.5%	$11.5M+188.2%	$4.0M+12.0%	$3.6M+28.6%	$2.8M+70.7%	$1.6M-23.3%	$2.1M+29.5%	$1.6M-71.4%	$5.7M-8.5%	$6.2M+37.8%	$4.5M+517.3%	$733K+45.5%	$504K
Non-Current Liabilities	$309K-24.5%	$410K-17.1%	$494K-10.7%	$553K+232.5%	$166K-44.9%	$302K-28.4%	$422K+146.6%	$171K+7627.0%	$2K-98.5%	$152K-37.7%	$244K-50.2%	$489K-17.6%	$593K+1.0%	$587K+1.5%	$578K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$330K-26.6%	$450K0.0%	$450K0.0%	$450K	N/A
Total Equity	$8.5M-40.3%	$14.3M+194.3%	-$15.2M-285.9%	$8.2M-71.9%	$29.1M-47.0%	$54.8M+504.8%	$9.1M-31.7%	$13.3M+23.3%	$10.8M-20.6%	$13.5M+720.7%	$1.6M-75.4%	$6.7M+294.1%	$1.7M-83.3%	$10.2M+7.1%	$9.5M
Retained Earnings	-$269.1M-8.8%	-$247.3M-22.0%	-$202.8M-26.7%	-$160.0M-6.0%	-$150.9M-19.0%	-$126.8M-13.5%	-$111.7M-14.4%	-$97.6M-15.7%	-$84.3M-19.2%	-$70.8M-9.6%	-$64.6M-9.3%	-$59.1M-15.8%	-$51.1M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$36.6M+167.5%	$11.1M-30.7%	$15.0M-41.2%	$14.6M-60.8%	$13.7M-53.4%	$16.0M-62.6%	$25.5M+111.0%	$37.3M+73.0%
Current Assets	$34.9M+176.4%	$9.3M-37.8%	$14.0M-42.1%	$13.6M-62.1%	$12.6M-54.8%	$14.9M-64.0%	$24.3M+132.0%	$35.9M+78.5%
Cash & Equivalents	$34.0M+207.9%	$8.3M-40.0%	$13.2M-43.3%	$12.6M-63.4%	$11.0M-57.3%	$13.9M-65.3%	$23.3M+143.5%	$34.3M+80.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%
Total Liabilities	$6.8M+8.7%	$6.4M-0.1%	$5.1M-48.4%	$5.2M-74.7%	$6.2M-60.1%	$6.4M-77.9%	$9.8M-62.1%	$20.7M-58.1%
Current Liabilities	$5.2M-10.7%	$4.9M-19.0%	$4.7M-49.4%	$4.9M-75.8%	$5.9M-61.3%	$6.0M-78.9%	$9.4M-63.0%	$20.3M-31.9%
Non-Current Liabilities	$1.5M+323.1%	$1.5M+295.9%	$309K-24.5%	$336K-22.2%	$361K-20.3%	$386K-18.6%	$410K-17.1%	$432K-97.8%
Total Equity	$29.9M+390.9%	$3.3M-59.6%	$8.5M-40.3%	$8.0M-47.3%	$6.1M-50.9%	$8.3M-34.0%	$14.3M+194.3%	$15.2M+154.2%
Retained Earnings	-$281.7M-8.6%	-$274.8M-8.2%	-$269.1M-8.8%	-$263.8M-7.7%	-$259.4M-12.6%	-$253.9M-10.7%	-$247.3M-22.0%	-$245.0M-25.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CLRB Cash Flow Statement

CLRB quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$19.5M	-$23.1M+51.4%	-$47.6M-47.0%	-$32.4M-28.4%	-$25.2M-11.8%	-$22.6M-62.0%	-$13.9M-19.1%	-$11.7M-2.2%	-$11.4M-3.8%	-$11.0M-33.1%	-$8.3M-0.8%	-$8.2M+7.1%	-$8.8M+3.4%	-$9.2M-39.0%	-$6.6M-10.3%	-$6.0M
Depreciation & Amortization	N/A	$214K-26.8%	$292K+51.6%	$192K+29.6%	$148K-1.0%	$150K+6.0%	$141K+6.5%	$133K+61.4%	$82K-94.7%	$1.5M+333.5%	$357K-1.6%	$363K-1.3%	$367K-13.6%	$425K-14.6%	$497K-15.0%	$585K
Stock-Based Compensation	N/A	$2.3M-47.0%	$4.3M+77.3%	$2.4M+65.9%	$1.5M+29.2%	$1.1M+140.4%	$468K-46.1%	$867K+20.2%	$721K-4.9%	$759K+43.4%	$529K+18.3%	$447K-47.4%	$850K-63.4%	$2.3M+54.5%	$1.5M+65.7%	$907K
Capital Expenditures	N/A	$6K-94.4%	$104K-87.9%	$864K+282.4%	$226K+59.9%	$141K+126.7%	$62K+154.1%	$25K-93.6%	$385K+11.0%	$347K+379.9%	$72K+23.6%	$58K+97.7%	$30K-80.0%	$148K+51.3%	$98K-17.5%	$118K
Free Cash Flow	N/A	-$23.1M+51.5%	-$47.7M-43.5%	-$33.2M-30.6%	-$25.4M-12.1%	-$22.7M-62.3%	-$14.0M-19.4%	-$11.7M+0.9%	-$11.8M-4.0%	-$11.4M-36.1%	-$8.4M-1.0%	-$8.3M+6.7%	-$8.9M+4.6%	-$9.3M-39.2%	-$6.7M-9.8%	-$6.1M
Investing Cash Flow	N/A	-$6K+94.4%	-$104K+87.9%	-$864K-282.4%	-$226K-59.9%	-$141K-126.7%	-$62K-154.1%	-$25K+92.6%	-$330K+4.8%	-$347K-379.9%	-$72K	N/A	N/A	N/A	-$2.1M-263.0%	$1.3M
Financing Cash Flow	N/A	$13.0M-78.8%	$61.4M+167.7%	$22.9M+138.7%	$9.6M+669.6%	$1.2M-97.9%	$60.5M+571.1%	$9.0M-39.9%	$15.0M+51.3%	$9.9M-37.7%	$15.9M	N/A	N/A	N/A	$7.9M-17.5%	$9.5M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$6.0M-17.5%	-$4.8M+48.4%	-$4.3M+60.2%	-$4.3M+53.4%	-$5.1M+63.8%	-$9.4M+29.8%	-$10.9M-13.7%	-$9.2M-13.6%
Depreciation & Amortization	N/A	N/A	$49K-27.9%	$52K-23.8%	$56K-15.8%	$56K-36.4%	$69K-2.0%	$69K+66.4%
Stock-Based Compensation	N/A	$452K-19.7%	N/A	N/A	N/A	$563K+23.9%	N/A	N/A
Capital Expenditures	$0	$3K	N/A	N/A	N/A	N/A	$61K-77.0%	$0
Free Cash Flow	-$6.0M	-$4.8M	N/A	N/A	N/A	N/A	-$11.0M-11.3%	-$9.2M
Investing Cash Flow	$0	-$3K	N/A	N/A	N/A	N/A	-$61K+77.0%	$0
Financing Cash Flow	N/A	N/A	$5.0M	$5.8M-67.0%	N/A	N/A	$0-100.0%	$17.6M-21.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CLRB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLRB quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Return on Equity	-255.3%+56.6pp	-311.9%	N/A	-389.9%-306.9pp	-83.0%-55.5pp	-27.6%+128.0pp	-155.6%-55.7pp	-99.8%+26.3pp	-126.1%-80.5pp	-45.6%+287.4pp	-333.1%-212.9pp	-120.2%+514.2pp	-634.4%-547.8pp	-86.6%-8.2pp	-78.4%
Return on Assets	-145.5%+29.5pp	-175.0%+139.5pp	-314.6%-167.3pp	-147.3%-82.4pp	-64.8%-39.1pp	-25.7%+89.3pp	-115.0%-27.1pp	-87.9%+17.4pp	-105.4%-65.0pp	-40.3%+32.0pp	-72.3%-12.3pp	-60.0%+98.2pp	-158.2%-81.6pp	-76.6%-6.3pp	-70.4%
Current Ratio	2.96+0.4x	2.58+2.2x	0.41-1.4x	1.78-7.4x	9.16-7.1x	16.26+12.2x	4.11-4.5x	8.60+3.6x	4.95-2.5x	7.47+6.7x	0.73-0.8x	1.56+0.9x	0.61-6.4x	7.00-4.5x	11.55
Debt-to-Equity	0.59-0.1x	0.69	N/A	1.48+1.3x	0.14+0.1x	0.07-0.3x	0.35+0.2x	0.14-0.1x	0.20+0.1x	0.13-0.1x	0.20+0.1x	0.07-0.2x	0.26+0.2x	0.04-0.1x	0.11

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-23.2%+66.3pp	-169.5%-89.5pp	N/A	-55.6%+41.1pp	-89.5%-82.1pp	-80.0%+133.1pp	N/A	-96.7%
Return on Assets	-18.9%+20.9pp	-50.8%-9.7pp	N/A	-30.4%+8.9pp	-39.8%-36.6pp	-41.2%+20.9pp	N/A	-39.3%+42.0pp
Current Ratio	6.66+4.5x	1.90-0.6x	2.96+0.4x	2.77+1.0x	2.15+0.3x	2.47+1.0x	2.58+2.2x	1.77+1.1x
Debt-to-Equity	0.23-0.8x	1.92+1.1x	0.59-0.1x	0.66-0.7x	1.02-0.2x	0.78-1.5x	0.69	1.37

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Cellectar Biosciences INC NEW CLRB	FY2025	N/A	-$21.8M	N/A	$13.5M	—
Edesa Biotech, Inc. EDSA	FY2025	N/A	-$7.2M	N/A	$28.3M	—
Tharimmune, Inc. THAR	FY2025	N/A	-$35.9M	N/A	$187.4M	—
Lisata Therapeutics, Inc. LSTA	FY2025	$170K	-$17.0M	N/A	$11.3M	—
Pulmatrix, Inc. PULM	FY2025	N/A	-$5.2M	N/A	$5.2M	—
SYNLOGIC INC SYBX	FY2025	$0	-$1.0M	N/A	$6.6M	—

Where Cellectar Biosciences INC NEW Ranks

Frequently Asked Questions

Is Cellectar Biosciences INC NEW profitable?

No, Cellectar Biosciences INC NEW (CLRB) reported a net income of -$21.8M in fiscal year 2025.

What is Cellectar Biosciences INC NEW's EBITDA?

Cellectar Biosciences INC NEW (CLRB) had EBITDA of -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cellectar Biosciences INC NEW's return on equity (ROE)?

Cellectar Biosciences INC NEW (CLRB) has a return on equity of -255.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cellectar Biosciences INC NEW's free cash flow?

Cellectar Biosciences INC NEW (CLRB) recorded an outflow of $23.1M in free cash flow during fiscal year 2025. This represents a 51.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cellectar Biosciences INC NEW's operating cash flow?

Cellectar Biosciences INC NEW (CLRB) recorded an outflow of $23.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Cellectar Biosciences INC NEW's total assets?

Cellectar Biosciences INC NEW (CLRB) had $15.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cellectar Biosciences INC NEW's capital expenditures?

Cellectar Biosciences INC NEW (CLRB) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cellectar Biosciences INC NEW spend on research and development?

Cellectar Biosciences INC NEW (CLRB) invested $11.5M in research and development during fiscal year 2025.

How many shares does Cellectar Biosciences INC NEW have outstanding?

Cellectar Biosciences INC NEW (CLRB) had 4M shares outstanding as of fiscal year 2025.

What is Cellectar Biosciences INC NEW's current ratio?

Cellectar Biosciences INC NEW (CLRB) had a current ratio of 2.96 as of fiscal year 2025, which is generally considered healthy.

What is Cellectar Biosciences INC NEW's debt-to-equity ratio?

Cellectar Biosciences INC NEW (CLRB) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cellectar Biosciences INC NEW's return on assets (ROA)?

Cellectar Biosciences INC NEW (CLRB) had a return on assets of -145.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cellectar Biosciences INC NEW's P/E ratio?

Cellectar Biosciences INC NEW (CLRB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $13.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Cellectar Biosciences INC NEW's price-to-sales ratio?

Cellectar Biosciences INC NEW (CLRB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $13.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Cellectar Biosciences INC NEW's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Cellectar Biosciences INC NEW (CLRB) held $13.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.1M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Cellectar Biosciences INC NEW's Piotroski F-Score?

Cellectar Biosciences INC NEW (CLRB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cellectar Biosciences INC NEW's earnings high quality?

Cellectar Biosciences INC NEW (CLRB) reported a net loss of $21.8M while operations used $23.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.